Lilly's fourth quarter 2013 adjusted EPS of $0.74 was a penny above
the Zacks Consensus Estimate but 13% below the year-ago EPS of
$0.85. Results were affected by the Dec 2013 entry of generic
competition for Cymbalta in the U.S. Revenues slipped 2% to $5.81
billion but surpassed the Zacks Consensus Estimate of $5.49
billion. Lilly expects to earn $2.72 - $2.80 per share in 2014. The
biggest near-term challenge for Lilly will be to replace the
revenues lost due to the Zyprexa and Cymbalta genericization. The
generic threat will continue to pose challenges with Evista losing
exclusivity in Mar 2014. On the flip side, the Animal Health
business and the diabetes franchise should provide some downside
support. We are also pleased to see Lilly pursuing small
acquisitions and in-licensing deals to boost its pipeline.
Indianapolis, Ind. based Eli Lilly and Company is a global
healthcare company with core products in a number of primary-care
pharmaceutical markets. Lilly generates revenues from its
pharmaceutical product and animal health segments. The
pharmaceutical product segment consists of several divisions:
neuroscience (Zyprexa, Cymbalta, Strattera, and Prozac),
endocrinology products (Humalog, Humulin, Byetta, Actos, Evista,
Forteo, and Humatrope), oncology (Alimta and Gemzar), and
cardiovascular (Cialis, ReoPro, Xigris, and Effient).
The company's portfolio includes Zyprexa (schizophrenia and
bipolar disorder), Gemzar (pancreatic cancer), Evista
(osteoporosis), Cymbalta (depression), Cialis (erectile
dysfunction), Strattera (attention deficit hyperactivity disorder -
ADHD), and Alimta (chemotherapy). The $6.5 billion purchase of
ImClone Systems in Nov 2008 brought with it blockbuster cancer
compound Erbitux. In addition, Lilly develops drugs in the areas of
antibiotics, growth hormones, anti-ulcer agents, cardiovascular
therapies and animal health products. These products (other than
Erbitux) are manufactured either at its own or leased facilities,
and are sold in approximately 120 countries around the world.
Over the past few years, Lilly has been actively seeking
acquisitions and in-licensing deals to boost its product portfolio
and pipeline. While the ImClone acquisition helped expand Lilly's
oncology pipeline and biotechnology capabilities, the Aug 2008
acquisition of SGX Pharmaceuticals, Inc. gave Lilly access to SGX's
fragment-based, protein structure guided drug discovery technology,
and several preclinical oncology compounds. The Jan 2007
acquisition of ICOS Corporation gave Lilly full control over
erectile dysfunction drug, Cialis.
Other acquisitions include those of Hypnion, Inc. (a
neuroscience drug discovery company focused on sleep disorders) and
Ivy Animal Health, Inc. (an applied research and pharmaceutical
product development company focused on the animal health industry).
Lilly also expanded its animal health business through the
acquisition of the European rights to some of Pfizer's animal
health products, consisting of vaccines, parasiticides and feed
additives for both companion and production animals, and the
acquisition of the animal health business of Janssen. Lilly also
acquired ChemGen Corp., which specializes in the development and
commercialization of innovative feed enzyme products that improve
the efficiency of poultry, egg, and meat production.
Lilly has collaboration agreements with several companies
including Bristol-Myers Squibb and Merck KGaA (Erbitux), Daiichi
Sankyo (Effient), Boehringer Ingelheim (diabetes) and TPG-Axon
Capital (solanezumab) among others.
Eli Lilly & Company (LLY): Read the Full
LILLY ELI & CO (LLY): Free Stock Analysis
To read this article on Zacks.com click here.